Charles River Laboratories Announces Second-Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
JPMorgan Downgrades Charles River Labs (CRL) to Neutral
August 8, 2024 5:55 AM EDTJPMorgan analyst Tycho W. Peterson downgraded Charles River Labs (NYSE: CRL) from Overweight to Neutral with a price target of $205.00 (from $270.00).
The analyst comments "As we noted yesterday in our first take, CRL reported a 2Q top- and bottom-line beat (with the latter aided by $0.30 worth of lower bonus accrual benefit) but took down guidance substantially due to an unexpectedly weaker demand environment in DSA. While buyside expectations assumed a guide cut to 2H24 on a slower pace of recovery in biotech within DSA, the magnitude... More
